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Abstract
Wilson disease (WD) is characterized by the accumulation of copper arising from a mutation in the ATP7B gene.
Penicillamine (PA) makes 10–50% of the patients with neurologic symptoms neurologically worse at the early stage of
administration. The aim of this study was to determine how the copper metabolism changes and whether the change
impairs the brain of toxic milk (tx) mice, an animal model of WD, during the PA administration. The free copper and protein-
bound copper concentrations in the serum, cortex and basal ganglia of tx mice with PA administration for 3 days, 10 days
and 14 days, respectively, were investigated. The expression of copper transporters, ATP7A and CTR1,was analyzed by real-
time quantitative PCR, immunofluorescence and Western blot. Then SOD, MDA and GSH/GSSG were detected to determine
whether the oxidative stress changed correspondingly. The results revealed the elevated free copper concentrations in the
serum and brain, and declined protein-bound copper concentrations in the brain of tx mice during PA administration.
Meanwhile, transiently increased expression of ATP7A and CTR1 was observed generally in the brain parenchyma by
immunofluorescence, real-time quantitative PCR and Western blot. Additionally, ATP7A and CTR1 were observed to locate
mainly at Golgi apparatus and cellular membrane respectively. Intense staining of ATP7A in the choroid plexus was found in
tx mice on the 3rd and 10th day of PA treatment, but rare staining of ATP7A and CTR1 in the blood-brain barrier (BBB).
Decreased GSH/GSSG and increased MDA concentrations were also viewed in the cortex and basal ganglia. Our results
suggested the elevated free copper concentrations in the brain might lead to the enhanced oxidative stress during PA
administration. The increased free copper in the brain might come from the copper mobilized from brain parenchyma cells
but not from the serum according to the ATP7A and CTR1 expression analysis.
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Introduction
Wilson disease (WD) is an autosomal recessive disease arising
from a mutation in the ATP7B gene, which results in the failure of
hepatocytes to excrete copper into bile, leading to the hepatic
copper accumulation and cell injury. Eventually copper is released
into the bloodstream and deposits in various other organs, notably
the brain, kidneys, and cornea. Copper incorporation into the
protein ceruloplasmin (Cp) is also impaired by dysfunction of
ATP7B, leading to the reduced circulating holoceruloplasmin.
The treatment for WD patients involves reversing the positive
copper balance. Chelators like penicillamine or trientine induce
negative copper balance by cupriuresis [1]. The pivotal role of
penicillamine in the initial treatment for WD patients with
neurologic symptoms has been a matter of debate for the risk of
neurological worsening for the past three decades. 10%–50% of
patients neurologically worsened by PA and 50% of them never
recovered to the level before treatment [2]. Trientine shares the
propensity of penicillamine to deteriorate neurologic symptoms
(about 25%) [3].
Previous study reported that free copper increased in the
cerebrospinal fluid (CSF) and serum in WD patients with the
neurologic manifestation during the penicillamine therapy [4].
Neurons were found an early and extensive death when treated
with copper in vitro, which mirrored the concentration of the CSF
of WD patients in previous report [5]. These findings indicated the
increased free copper concentration in the brain might associate
with the neurologic deterioration. The likely explanation for the
drugs worsening the neurological symptoms was that a further
elevation of copper level in the brain followed the mobilization of
large stores of copper in the liver and/or the brain [4,6,7]. But
there has been no direct evidence supporting the hypothesis yet.
Copper transport into cells is mediated by copper transporter1
(CTR1), which mediates copper uptake into mammalian cells,
through the copper-stimulated endocytosis and degradation of
CTR1 [8]. ATP7A and ATP7B are both copper transport proteins
which participate in copper efflux out of cells,whereas ATP7A is
the dominating copper transporter in neurons [9]. ATP7A moves
towards the plasma membrane and removes excess copper in the
presence of elevated extracellular copper concentrations [10].
Earlier studies reported the expression of the copper transpoter-
s,ATP7A and CTR1, was higher in brain barriers than that in
brain parenchyma by in situ brain perfusion technique with
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achieved through the blood-brain barrier(BBB) [11,12].
In the serum copper is mainly carried by Cp, while the residue
bound to albumin or small molecules. Free copper, which is
commonly defined as the copper not covalently bound to Cp in the
blood, is loosely bound to albumin and small molecules. Free
copper, which is about 5–15% of serum copper in normal people,
greatly expanded in WD patients and diffused out of the vascular
compartment into extracellular fluids and tissues with toxic effects
[13].The free copper concentration is assessed with the calculation
of the serum non Cp-bound copper [1]. However, it was suggested
copper transported into the brain through the blood-brain barrier
(BBB) as free copper ions but not as albumin-bound copper [11].
The estimation of copper concentration by the traditional method
didn’t eliminate the role of albumin or other proteins which bound
unnecessary copper and lessened the toxic effect.
The toxic milk (tx) mouse is a naturally occurring genetic and
phenotypic model of WD derived from the wild-type (DL) mouse
[14]. The mouse contains a methionine to valine substitution
(M1356V) that renders the ATP7B protein dysfunctional and
results in copper accumulation, which commences in the 3rd
postnatal week, in a distribution resembling that observed in
human WD cases. An increase of copper in the liver and the brain
has been well characterized in tx mice [15]. In this study we
investigated the concentrations of free copper and protein-bound
copper in the serum and the brain tissue, separately, by a different
method of ultrafiltration during PA treatment [16]. The expression
of ATP7A and CTR1 was also detected to estimate the copper
transporting activity in the brain. Furthermore we examined the
possible neurotoxicity during the treatment. Superoxide dismutase
(SOD) and reduced glutathione/oxidized glutathione (GSH/
GSSG) ratio were measured as intracellular indicators of
antioxidant responses, while the malondialdehyde (MDA) content
as a lipid peroxidation index.
Results
Copper concentrations
The average serum free copper concentration detected by
ultrafiltration method was about 8.9% of serum copper concen-
tration, the sum of free copper and protein-bound copper, in
control group of tx mice,while in DL mice it was 1.9%. The free
copper concentrations in tx mice serum significantly elevated on
the 3rd day after persistent PA administration (P,0.05), then
declined progressively and below the level of control mice on the
14th day (Fig. 1). Obviously the free copper concentrations in DL
mice were lower than tx mice and also lightly increased 3 days
after PA administration (P.0.05). The protein-bound copper
concentrations in tx mice serum were significantly lower than that
in DL mice. In tx mice the mean protein-bound copper
concentrations was nearly 200 ug/L and almost 2-fold increased
on the 3rd day of PA treatment and kept the level up to the 14th
day (P,0.01). In normal mice the copper bound to protein was
slightly decreased during the PA treatment.
Figure 2 shows the free copper concentrations in the cortex and
basal ganglia of tx mice were slightly higher than that of DL mice
and also it shows the same tendency as that of the serum after
administration, which significantly elevated (P,0.05)on the 3rd
day and gradually lowered on the 10th and the 14th day. The free
copper concentrations in DL mice were slightly decreased during
the treatment. The protein-bound copper concentrations in the
cortex and basal ganglia of the control tx mice were approximately
2-fold higher than that of DL mice,and gradually decreased along
the administration compared with the control group (P,0.01). On
the 14th day the protein-bound copper concentrations almost 25%
decreased, while in DL mice the concentrations also slightly
decreased during the administration.
Relative mRNA expression of ATP7A and CTR1
To make sure b-actin mRNA expression was unchanged during
the PA treatment,the expression stability was analyzed by absolute
standard curve method. The copies of b-actin did not change
prominently in the cortex and basal ganglia of tx mice or DL mice
during the PA treatment. Figure 3 showed the stable expression of
b-actin mRNA in the basal ganglia of the mice.
Relative abundance values for ATP7A and CTR1 were
compared between the mice with PA administration and the
controls (Fig. 4). Compared to the controls, the mRNA expression
of ATP7A 4-fold increased (P,0.01) on the 3rd day in tx mice
cortex after PA treatment, and 6-fold (P,0.01) increased in the
basal ganglia. But on the 10th day it decreased to the level before
administration, and further, lowered down to approximately 0.4-
fold (P,0.05) in the cortex and 0.5-fold (P,0.05) in the basal
ganglia as high as the controls on the 14th day. In DL
mice,ATP7A mRNA expression 1.7-fold increased (P,0.05) in
the cortex and 1.8-fold (P,0.05) in the basal ganglia on the 3rd
day, and 0.5- and 0.7-fold decreased (P,0.05) in the cortex and
basal ganglia on the 10th day, respectively, while 0.4-fold
decreased (P,0.05) in both locations on the 14th day.
CTR1 mRNA expression increased by 6.9-fold (P,0.01) in the
cortex and 9.1-fold in the basal ganglia of tx mice on the 3rd day
after administration, but on the 10th day, it decreased significant-
ly. Compared to controls, CTR1 expression increased by 1.9-fold
(P,0.05) in the cortex and by 2.1-fold (P,0.05) in the basal
ganglia on the 10th day, while by 1.8- and 2.3-fold (P,0.05) on
the 14th day in the cortex and basal ganglia, respectively. In DL
mice, CTR1 expression increased by 2.5-fold (P,0.05) in the
cortex and by 2.15-fold (P,0.05) in the basal ganglia on the 3rd
day of administration as compared to controls. Then it dropped
back to the level of the control in both locations on the 3rd and the
10th day.
Immunofluorescence of ATP7A and CTR1
Immunofluorescence staining of frozen brain sections with
antibody to ATP7A was scarcely observed in all DL mice brain
sections, but weak staining in the layer 5 pyramidal neurons in the
cortex, that is, internal pyramidal layer neurons (data not shown).
ATP7A antibody also stained the internal pyramidal layer neurons
in the control tx mice. After PA administration, intense ATP7A
staining was generally present in the brain on the 3rd and the 10th
day, including the cortex, hippocampus, caudate putamen (CPu),
thalamus and choroid plexus in lateral cerebral ventricles (Fig. 5),
and the location with the most intense staining was the internal
pyramidal layer neurons. On the 14th day, ATP7A staining
generally declined in the brain sections.
Immunofluorescence staining of CTR1 showed the staining was
seldom present in the brain tissues of DL mice with or without PA
treatment (Data not shown). CTR1 staining in the brain sections
of the control group of tx mice was also scarcely observed. On the
3rd day of administration, CTR1 staining was generally but not
intensely detected in the tx brain tissues, including internal
pyramidal layer cells in the cortex, hippocampus, Cpu and
thalamus. On the 10th day, the CTR1 staining was still present in
brain cells, but almost disappeared on the 14th day. CTR1
staining was not detected in the choroid plexus or the endyma cells
in tx mice brain with or without PA treatment (Fig. 6).
Co-localization experiment showed the localization of ATP7A
and CTR1 in brain cells during the PA treatment. We used
Impact of Penicillamine on the Brain of Tx Mice
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37709Figure 1. Detection of the free copper and protein-bound copper in the serum of tx and DL mice. Tx and DL mice were subjected to PA
intragastric administration for 3 days, 10 days and 14 days, respectively. Mice without PA were controls. (A)The free copper concentrations in the tx
mice serum increased on the 3rd day, and decreased on the 10th and the 14th day. The free copper concentrations didn’t change significantly in DL
mice. (B)The protein-bound copper concentrations in the serum 2-fold increased on the 3rd day compared to the controls and kept the level on the
10th and the 14th day, while slightly decreased along the administration in the serum of DL mice.(* P,0.05;** P,0.01).
doi:10.1371/journal.pone.0037709.g001
Figure 2. Detection of the free copper and protein-bound copper in the brain of tx and DL mice. (A)(C)The free copper concentrations in
the cortex and basal ganglia of tx mice increased on the 3rd day and decreased on the 10th and 14th day,respectively. In DL mice the free copper
decreased slightly along the administration. (B)(D) The protein-bound copper concentrations in the cortex and basal ganglia of tx and DL mice all
decreased along the administration. The protein-bound copper concentrations in tx mice were about 2-fold higher than that of DL mice. (* P,0.05;
** P,0.01).
doi:10.1371/journal.pone.0037709.g002
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apparatus and viewed the co-localization of ATP7A and
GOLPH2 under the oil immersion lens. Figure 7 showed that
ATP7A mainly located at Golgi apparatus in the internal
pyramidal layer of brain of tx mice during the PA treatment,
while ATP7A staining seemed to exceed the scope of GOLPH2
staining on the 3rd day of the PA treatment. Meanwhile, we used
NKCC1, the Na+/K+/2Cl2 cotransporter located at cellular
membrane, to label the cellular membrane. Figure 8 showed
CTR1 co-located with NKCC1 in the internal pyramidal layer of
cerebrum of tx mice, and it indicated that CTR1 located mainly at
cellular membrane in tx mouse brain during the PA treatment.
In brain sections of tx mice intense ATP7A staining generally
located in cells expressing CTR1. Figure 9 shows the co-
localization in the Cpu of tx mice with 3 days PA administration.
ATP7A expression in neurons was investigated using microtubu-
lin-associated protein 2(MAP2), which was generally detected in
neurons. This suggested that PA induced increased expressions of
ATP7A and CTR1 in neurons. Previous study revealed that
ATP7A and CTR1 achieved to transport copper into brain
through BBB. The structure basis of BBB is composed of capillary
endothelium and astrocytic endfeet, which ensheath the capillary
Figure 3. Absolute quantitation of b-actin in the cDNA from
tissue. The copies of b-actin analyzed by absolute standard curve
method did not change prominently in the basal ganglia of tx mice or
DL mice during PA treatment.
doi:10.1371/journal.pone.0037709.g003
Figure 4. ATP7A and CTR1 mRNA expression in the brain of tx and DL mice. (A)(B)(C)(D)The ATP7A and CTR1 mRNA expression in the cortex
and the basal ganglia increased significantly on the 3rd day, and declined close to the level of the control on the 10th and the 14th day. In DL mice
mRNA expression of ATP7A and CTR1 also transiently increased on the 3rd day. In tx and DL controls, mRNA expression value was defined as 1.0.
(* P,0.05, ** P,0.01).
doi:10.1371/journal.pone.0037709.g004
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used the cytoskeletal marker protein GFAP to identify astrocytes
and astrocytic endfeet, and viewed little co-localization of ATP7A
or CTR1 with GFAP as well as endothelial cells nucleus marked
by DAPI in the basal lamina of BBB.
Western blot analysis for ATP7A and CTR1
To verify the changes of immunofluorescence staining of
ATP7A and CTR1, the cortex and basal ganglia tissues of the
mice with or without PA administration were examined with
Western blot. The specificity of the anti-ATP7A and anti-CTR1
primary antibodies was confirmed by the protein bands with the
size 170 kDa and 25 kDa, respectively. Compared with controls,
the ATP7A expression 1.5-fold increased (P,0.01) in the cortex,
and 2.6-fold (P,0.01) increased in the basal ganglia of tx mouse
on the 3rd day after PA treatment (Figure 10). On the 10th day a
2.1-fold increased ATP7A expression was observed in the cortex as
well as a more than 2.9-fold increase in basal ganglia. On the 14th
Figure 5. Detection of ATP7A by immunofluorescent staining (red) in the coronal brain slices of tx mice. Tx mice were subjected to PA
administration for 3 days, 10days and 14days, respectively. (A) Internal pyramidal layer. ATP7A immunoreactivity staining was weak in internal
pyramidal layer neurons in the control mice cortex, but increased significantly on the 3rd and the 10th day, then decreased on the 14th day.
(B)hippocampus CA1 region, (C)caudate putamen(CPu), (D) central medial thalamic nucleus(CM),(E)choroid plexus in the lateral cerebral
ventricles.ATP7A staining was weak in cells of hippocampus CA1 region, CPu, CM and choroid plexus in the control mice, and significantly increased
on the 3rd day and the 10th day during PA administration, and declined on the 14th day. Scale bars=30 um.
doi:10.1371/journal.pone.0037709.g005
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group. In DL mice ATP7A expression did not change in the
cortex or basal ganglia during the PA administration.
CTR1 expression 2.2-fold (P,0.01) and 2.6-fold (P,0.01)
increased on the 3rd day in tx mouse cortex and basal ganglia,
respectively, while on the 10th day it 2.9-fold (P,0.01) and 3.1-
fold (P,0.01) increased in tx mouse cortex and basal ganglia,
respectively. CTR1 expression declined to the baseline on the 14th
day in both regions above. In DL mice CTR1 expression did not
change in the cortex and basal ganglia during the PA adminis-
tration (Figure 11).
Oxidative-stress in the central nervous system
The activity of SOD in the cortex and the basal ganglia of tx
and DL mice did not change during the two weeks PA
administration. MDA was measured to estimate the lipid
Figure 6. Detection of CTR1 by immunofluorescent staining (red) in the coronal brain slices of tx mice. (A) Internal pyramidal layer.
There was almost no CTR1 immunoreactivity staining in the internal pyramidal layer neurons in control mice cortex. The staining presented on the
3rd and the 10th day, but declined on the 14th day during PA treatment. (B) hippocampus CA1 region, (C) caudate putamen (CPu), (D) central medial
thalamic nucleus(CM). CTR1 staining was scarcely observed in cells of hippocampus CA1 region, CPu, and CM in the control mice, but presented on
the 3rd and the 10th day during PA treatment, and declined on the 14th day. (E) choroid plexus in lateral cerebral ventricles. There was rare staining
in the choroid plexus cells in tx mice with or without PA administration. Scale bars=30 um.
doi:10.1371/journal.pone.0037709.g006
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concentrations in the cortex and the basal ganglia of tx mice
increased on the 10th (P,0.05) and the 14th day (P,0.01) of the
administration compared to controls. But it did not show any
difference in DL mice. Analysis of GSH/GSSG ratios revealed
that the GSH/GSSG declined gradually in the brains of tx mice
after PA administration (P,0.01). It declined from the 3rd day of
administration in the cortex and from the 10th day in the basal
ganglia. It did not demonstrate the variation of GSH/GSSG ratios
in DL mice during PA administration (Fig. 12).
Discussion
The neurological deterioration of WD patients during the
chelator treatment has puzzled the neurologists for years. In a
double blind study the spikes of the increased free copper levels in
the serum associated in time with the WD patients’ neurologic
worsening [17]. But there are few researches on the change of
copper in brain during the chelator treatment. In this study, we
aimed to investigate the fluctuation of copper in the tx mice brain
during PA treatment.
In our experiment the main content of serum copper in tx mice,
which is the protein-bound copper, was significantly lower than
DL mice. This was consistent with the reduced Cp due to the
mutant ATP7B gene and verified this model. The transient
increase of free copper in the serum of tx mice in the early days of
PA administration was accordant with the previous report about
WD patients [17]. Meanwhile, serum protein-bound copper also
increased in tx mice during PA administration. This suggested that
PA chelated a large amount of copper in the liver, followed by the
increased copper in the serum. The mobilized copper mostly
bound to the non-Cp proteins, such as albumin, which could be
held-up by the ultrafiltration device and detected. When beyond
the binding capability of serum proteins, the copper loosely bound
to small molecules like amino acids or remained free, then filtrated
through the membrane. In DL mice, the protein-bound copper
was slightly decreased during the PA treatment, which might
attributed to that PA reduced the copper potentially delivered to
Cp by ATP7B in the liver.
In cells most of the copper is incorporated to the proteins
including ceruloplasmin, cytochome oxidase, superoxide dismu-
tase and metallothionein [18]. In our study most of the copper
Figure 7. Co-localization of ATP7A and GOLPH2 in the internal pyramidal layer. The slices were from tx mice subjected to PA
administration for 3 days, 10days and 14days, respectively. Golgi apparatus were labeled with GOLPH2. ATP7A(red) staining mainly co-located with
GOLPH2(green) in the internal pyramidal layer of tx mice during the PA treatment, and the scope of ATP7A staining exceeded that of GOLPH2 on the
3rd day of the PA treatment. Scale bars=10 um.
doi:10.1371/journal.pone.0037709.g007
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device,and the residues, which were defined as free copper,
included the copper ions and the copper binding with GSH,
amino acid or other small molecules. These free copper elevated at
the early stage of PA administration in the cortex and basal
ganglia, whereas the protein-bound copper decreased gradually. It
indicated PA removed copper from the brain at the early stage of
treatment and induced the increase of free copper concentrations
in tissue. Herein we provided the evidence of copper mobilized by
PA in the brain, though it is still not sure whether the free copper
came from the brain or the liver. What is interesting is that the
protein-bound copper concentrations in the basal ganglia were
approximately 25 mg/kg protein higher than those in the cortex.
This may be one of the reasons for the very susceptibility of the
basal ganglia in WD patients.
We further documented the transient increased mRNA
expression of ATP7A and CTR1 after PA administration, and
the immunofluorescence results demonstrated the same tendency
as transcription, while the Western blot experiment further verified
the transiently increased protein expression. It has been reported a
decline in ATP7A expression in the cortex from the early postnatal
period to adulthood in mice, and our data verified the feature that
in the adult the ATP7A staining was the most intense in layer 5
pyramidal neurons of the cortex [19]. Our data showed enhanced
ATP7A expression was ubiquitously observed in the brain of tx
mice 3 days after PA treatment, and still the most intense in layer 5
pyramidal neurons. The experiment revealed that ATP7A
primarily expressed in internal pyramidal layer neurons, and PA
induced the increase of ATP7A expression generally in the brain
of tx mice but not in DL mice. It is known that all the key
regulators,including ATP7A and CTR1,mediating copper homeo-
stasis in peripheral tissues are also present in the brain [9]. When
copper elevated, ATP7A left the TGN and facilitated copper
excretion. Copper also induced the mRNA expression and might
regulate the transcription of ATP7A in a fish cell line [20]. In our
study the increased ATP7A expression was in accordance with the
concentrations of free copper,which suggested that the elevated
expression of ATP7A may be induced by the increased copper in
the brain on the early phages of PA treatment. Co-localization
experiment revealed that ATP7A mainly located at Golgi
apparatus during the PA treatment, while the scope of ATP7A
immunostaining exceeded that of GOLPH2 staining in brain cells
of tx mice on the 3rd day of the PA treatment. It indicated the
alteration in subcellular localization of ATP7A during the PA
Figure 8. Co-localization of CTR1 and NKCC1 in the internal pyramidal layer. The slices were from tx mice subjected to PA administration
for 3 days, 10days and 14days, respectively. Cellular membranes were labeled with NKCC1. CTR1(red) staining mainly co-located with NKCC1(green) in
the internal pyramidal layer in cortex of tx mice during the PA treatment. Scale bars=10 um.
doi:10.1371/journal.pone.0037709.g008
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TGN to the vesicles induced by increased copper concentration.
The same tendency of the free copper concentrations in the
serum and the brain tissues during PA administration brought
about the question that whether the increased free copper in the
brain came from the serum, or directly mobilized from the brain
cells. The mechanism of copper transporting into the brain is still
unclear. Previous data showed that the ATP7A and CTR1
expressed more profoundly in the brain barrier fractions (cerebral
capillaries and choroid plexus) than in the brain parenchyma, and
the copper transported into the brain primarily occured via the
BBB as free ions [11,12]. Our data revealed most of the copper
mobilized by PA in the serum was bound to proteins. If the free
copper in the brain came from the serum, the copper transporters
at BBB should be observed. In fact we found CTR1 and ATP7A
hardly expressed in cells around BBB, which didn’t support the
Figure 9. Immunofluorescent staining of ATP7A and CTR1 in neurons and astrocytes in the Cpu. The slices were from tx mice with 3 days
PA administration. Neurons and astrocytes were labeled with MAP2 and GFAP, respectively. (A) ATP7A (red) immunoreactivity co-localization with
CTR1 (green) in CPu (yellow arrows). (B)ATP7A (red) immunoreactivity co-localization with MAP2 (green) in CPu(yellow arrows). (C)ATP7A (red)
immunoreactivity demonstrated little expression at BBB, which was formed by vascular endothelial cells (blue arrows) and astrocytic endfeet (green)
ensheathing the endothelium. (D)CTR1 (red) immunoreactivity demonstrated little expression with vascular endothelial cells (blue arrows) and
astrocytic endfeet (green). Scale bars=30 um.
doi:10.1371/journal.pone.0037709.g009
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37709Figure 10. Western blot analysis of ATP7A in the cortex and basal ganglia of tx and DL mice. (A) ATP7A expression increased significantly
(P,0.01) on the 3rd day and 10th day in tx mouse cortex during PA treatment, and declined closed to the level of the control on the 14th day. ATP7A
expression did not change in DL mice during PA treatment. (B) ATP7A expression increased significantly (P,0.01) on the 3rd day and 10th day in tx
mouse cortex, and declined closed to the level of the control on the 14th day, while it did not change in DL mice. Relative protein quantified as
compared with tx or DL controls (normalized to 1.0). **p,0.01 was considered significantly different from the control.
doi:10.1371/journal.pone.0037709.g010
Figure 11. Western blot analysis of CTR1 in the cortex and basal ganglia of tx and DL mice. (A) CTR1 expression increased significantly
(P,0.01) on the 3rd day and 10th day in tx mouse cortex, and declined closed to the level of the control on the 14th day. CTR1 expression did not
change in DL mice during the PA treatment. (B) CTR1 expression increased significantly (P,0.01) on the 3rd day and 10th day in tx mouse cortex, and
declined closed to the level of the control on the 14th day, while it did not change in DL mice. Relative protein quantified as compared with tx or DL
controls (normalized to 1.0). **p,0.01 was considered significantly different from the level of the control.
doi:10.1371/journal.pone.0037709.g011
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Compared with the weak signal before PA treatment, the ATP7A
signal was abundant in the choroid plexus during two weeks
treatment. It was likely that ATP7A played a role on regulating
copper concentration in the brain and the CSF. The findings of in
situ brain perfusion studies suggested copper was utilized and
released into the CSF via the interstitial fluid and removed by the
BCB from the CSF to blood [12]. Subsequently the increased
expression of ATP7A might suggest that ATP7A exported the
excess copper mobilized by PA from the brain cells, then the free
copper increased in interstitial fluid which in turn led to the higher
expression of ATP7A in the choroid plexus and secreted more
copper into CSF.
CTR1 transcription didn’t appear to change as a function of Cu
status in mammal cells [21,22]. But in our work CTR1 staining
and protein expression paralleled the transient increase of the
Figure 12. Oxidative-stress-related biomarkers assay in the cortex and the basal ganglia of the mice. (A)(B)SOD activity did not show
change in tx or DL mice during the administration. (C)(D) MDA concentrations slightly increased during PA administration in the cortex and basal
ganglia of tx mice but not in DL mice. (E)(F)GSH/GSSG ratios decreased gradually along the administration in the cortex and basal ganglia of tx mice,
but not in DL mice. (* P,0.05; ** P,0.01).
doi:10.1371/journal.pone.0037709.g012
Impact of Penicillamine on the Brain of Tx Mice
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e37709mRNA expression with the increased signal in the cortex and the
basal ganglia during the PA treatment, especially in layer 5
pyramidal neurons. CTR1 mostly located at the plasma
membrane,where it functioned in uptake of copper. Its increased
expression conflicted with the increasing of ATP7A, which played
the opposite role of CTR1. This phenomenon may be explained
by the following feedback mechanism. The brain cells of tx mice
had been accommodated to the copper accumulation for long.
However, the copper was quickly and indiscriminately chelated by
PA, and the protein-bound copper, which performed the major
physiologic function in the whole cells, decreased quickly during
the PA treatment. Therefore, cells had to ingest the extracellular
copper, reactively, to adjust the change and to meet the
physiologic needs.
We suggested that the excessive oxidative stress might occur in
the brain of tx mice after PA treatment. Copper induces oxidative
stress by two mechanisms. First, it was suggested that reaction of
Cu(I) with hydrogen peroxide and re-reduction of Cu(II) by
superoxide via Fenton and Haber-Weiss chemistry yielded
hydroxyl radicals [23,24,25]. Second, exposure to excessive copper
significantly decreases the glutathione level which is the major
water-soluble antioxidant in cells and directly reduces most of the
ROS [26]. Copper-overloaded rats exhibited oxidative injuries
with decreased GSH and increased MDA in the brain [27,28].
MDA also increased in the livers of rats with elevated copper [27].
In our study GSH/GSSG ratios decreased in the cortex and basal
ganglia and this indicated declined reductive capacity and
antioxidation during PA treatment. The increased MDA, the
lipid peroxidation index, implied the increased oxidative stress and
cellular damage. Though MDA and GSH/GSSG decreased, the
SOD levels remained in our study. SOD protected cells from
oxygen free radical by catalyzing the removal of O2
2. Now the
change of SOD activity induced by copper was not unanimous in
different studies [28,29,30,31]. Different copper concentrations
may result in different adjustment of the activity of SOD. Whether
SOD is involved in the defence of copper-induced oxidative
damaged is still controversial.
The tx mice did not demonstrate neurologic symptoms for
lifetime. Nevertheless, in our study we found the evidence of
increased free copper and increased oxidative biomarkers in the tx
mice brain during PA administration. It suggested the neurotox-
icity of PA administration in tx mice, even which didn’t showed
significant abnormalities of central nervous system. We presume
two weeks administration may be too short to lead to prominent
brain damage. Some of WD patients didn’t demonstrate
neurologic worsening during PA treatment, even suffered to
obvious neuroligic symptoms. We suppose other factors, such as
mutation styles, involved in the brain reacting to the chelator
treatment.
In conclusion, the present study revealed the elevated free
copper and declined protein-bound copper concentration in the
cortex and basal ganglia of tx mice accompanied by general
transiently increased of ATP7A and CTR1 in the brain during PA
treatment. The scarce expression of ATP7A and CTR1 in the
BBB and the increased ATP7A in choroid plexus suggested that
the increased free copper in the brain might be mobilized from the
brain parenchyma but not the serum. The declined oxidative
biomarkers GSH/GSSG ratio and MDA concentrations indicated
the oxidative stress raised by chelator treatment and this might be
due to the increased free copper in the parenchyma. The increased
free copper and oxidative stress partly explains the neurological
deterioration of WD patients with PA treatment.
Materials and Methods
Ethic statement
All animal procedures were conducted in accordance with and
approved by the animal ethics guidelines of the Institutional
Animal Care and Use Committee of Sun Yat-sen University
(ethics approval number20100603005). Strict attention was given
to the care and use of animals according to Chinese Law. All
efforts were made to minimize the number of animals used and
their suffering.
Animals
Toxic milk mutant mice (tx mice) and control mice (DL mice)
were kindly presented by professor Julian. Mercer(School of Life
and Environmental Sciences,Deakin University, Australia) and
arose in the Laboratory Animal Center of Sun Yat-sen University,
Guangzhou, China. Mice were housed in a temperature-
controlled, 12:12 light/dark room and were allowed free access
to water and food. Pups of tx mice required fostering in order to
survive and were routinely cross fostered within 5 days of birth to
DL mice that had produced litters at the similar time. All mice
used in this study were 16 weeks old (the peak time of copper
deposition in tx mice).
Reagents and antibodies
The chemical was purchased from the following sources: D-
Penicillamine (PA)(sigma), antibodies for immunofluorescence:
goat anti-ATP7A antibody(goat anti-human), goat anti-NKCC1
antibody(Santa, USA), rabbit anti-CTR1 antibody(Novus biolog-
icals, USA), rabbit anti-GOLPH2 antibody(Beijing Biosynthesis
Biotechnology, China), mouse anti-microtubulin-associated pro-
tein 2(MAP2) antibody (Boster, China), mouse anti glial fibrillary
acidic protein (GFAP) antibody (Cell signaling technology, USA).
The following were used as secondary antibodies: Cy3-conjugated
goat antirabbit immunoglobulin (Proteintech group, USA); Cy3-
conjugated donkey antigoat immunoglobulin (Proteintech group,
USA); and FITC-conjugated goat antimouse immunoglobulin
(Proteintech group, USA), antibodies for Western blot: chicken
anti-ATP7A antibody (Abcam,USA), rabbit anti-CTR1 antibo-
dy(Novus biologicals, USA), secondary antibodies: peroxidase anti-
chicken IgG (Proteintech, USA), peroxidase-conjugated anti-
rabbit IgG.
Experiment design
PA was dissolved in deionized water and given to mice (tx and
DL mice) with intragastric administration at doses (200 mg/kg/d)
in 2 divided dosages for 3 days, 10 days or 14 days respectively. Tx
mice with PA were model intervention groups, and DL mice with
PA were normal intervention groups (n=5 for each time point in
each index as following). Mice (tx and DL mice) given with
deionized water through intragastric administration were taken as
blank control groups.
Serum and tissue free and protein-bound copper
concentration analysis
Animals (n=5 for model intervention group and normal
intervention group, n=3 for both blank control groups, in each
time point) euthanized by injection of chloral hydrate (350 mg/kg
body). Blood samples were taken from the retrobulbar plexus. For
serum preparation blood samples were centrifuged at room
temperature for 10 mins. Animals were sacrificed by decapitation
and cortex and basal ganglia samples were collected. Brain
samples were homogenized in ten times the volumes of the buffer
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100000 g at 2uC [32]. The protein concentration of supernatant
was quantitated by BCA protein assay kit (Thermo Scientific). The
supernatant and serum samples were ultrafiltrated by the
ultrafiltration centrifugal filter devices(Millipore, 3 kD) with low
binding regenerated cellulose membrane. To retain albumin
which binds much of the copper in blood except ceruloplasmin,
and metallothionein which binds most of the copper in cells, we
selected the type of 3 kD. The proteins larger than 3 kD molecular
weight in the serum and homogenate of cortex and basal ganglia
were held up by the ultrafiltration centrifugal filter devices
(Millipore, 3 kD) in the concentrate. The copper being free ion
and the copper binding with small molecules were in the filtrate (in
this work we defined it as free copper). The filtrate and the
concentrate were wet-ashed with the same volume of nitric acid.
And copper concentrations were determined by air/acetylene
flame atomic absorption spectrometry, using a Hitach Z5000
spectrophotometer.
Real-Time quantitative PCR
Animals were treated with PA or deionized water as described
above (n=5 for model intervention group and normal interven-
tion group, n=3 for both blank control groups, in each time
point). Cortex and basal ganglia tissues were homogenated in
Trizol reagent and total RNA was isolated. Two micrograms of
RNA was used to synthesize single-strand cDNA by PrimeScript
RT-PCR Kit (Takara, Japan).The resulting cDNA was used for
Real-time PCR gene expression analysis of CTR1 and ATP7A.
The specific primers for Atp7A(59-AAACCTTGCGAGAAG-
CAATTG, and 59-GGGCA AAAGAGGTGTTTCCA),CTR1
(59- TGATGATGATGCCTATGACCT, and 59-G AAGA-
TAGCCCGAGAGGGTC) and b-actin (59-GACAGGATGGCA-
GAAGGA GATTACT, and 59-TGATCCACATCTGCTG-
GAAGGT). Real time PCR was performed in triplicate on a
DNA Engine Option (MJ Research) using a SYBR Green I kit
(Takara, Japan).The following protocol was used for all genes:
denaturation: 10 min-95uC;amplification and fluorescence acqui-
sition (36 cycles): 15 s — 95uC, 10 s 60uC; 10 s — 72uC with a
single fluorescence measurement; melting curve: from 40uCt o
99uC, 0.1uC/s heating rate and continuous fluorescence measure-
ment. Specificity of all products was verified by melting-curve
analysis and by analysis on agarose gels. Abundance data for each
gene is expressed as fold change. Samples were run in triplicate on
each plate and the results were analyzed with the relative standard
curve method. To make sure b-actin is a suitable reference
gene,the expression stability was analyzed at the beginning of the
experiment. A pair of specific primers for b-actin (TGCTGTC-
CCTGTATGCCTCT,TCATCGTACTCC TGCTTGCT) was
designed. The PCR product (676 bp) purified by E.Z.N.AH.
Cycle-Pure Kit (Omega, USA) was determined by Beckman-
coulter DU 800 spectrophotometer for the DNA concentration.
Total DNA copies were calculated by a free software offered
online by URI Genomics & Sequencing Center (http://www.uri.
edu/research/gsc/resources/cndna.html), and purified PCR
product was used as defined template of b-actin to perform a
standard curve. The copies of b-actin in the cDNA from tissues
was analyzed by absolute standard curve method.
Immunofluorescence of CTR1 and ATP7A
Animals were treated with PA or deionized water as described
above (n=5 for model intervention group and normal interven-
tion group, n=3 for both blank control groups, in each time
point). Mice were anesthetized with chloral hydrate (350 mg/kg
body) and perfused in the left ventricle with saline followed by 4%
polyoxymethylene in 16PBS, pH 7.4. The brain was extracted
and post-fixed 6 h in 4% polyoxymethylene, then incubated
overnight in 20% sucrose, then 30% sucrose and then embedded
in Tissue-Tek Optimal Cutting Temperature compound(Sakura
Fine Technical, Tokyo, Japan)at 220uC. Coronal section of
10 um were sliced and placed onto poly-L-lysine-coated slides.
Slides were rehydrated in phosphate-buffered saline (PBS), and
then permeabilized with 0.03% Triton X-100 in PBS for 15 min
at room temperature. Slides were washed in PBS and blocked for
1 h at room temperature using 5% bovine serum albumin in PBS.
Slides were then incubated overnight at 4uC with primary
antibody (CTR1 at 1:100 or ATP7A at 1:300) in dilution buffer
(1%BSA, in PBS). Unbound antibodies were removed by washing
in PBS. After that the slides were incubated for 1 h in the dark
with fluorescein isothiocyanate (FITC)-conjugated IgG, or Cya-
nine3 (Cy3) -conjugated donkey IgG. After a further wash in PBS,
the slides were incubated with 4,6-diamidino-2-phenylindole
(DAPI) at 500 ng/ml diluted in PBS for 15 minutes, and analyzed
using an Olympus microscope.
Western blot analysis
Mice were sacrificed (n=4 for model intervention group, n=3
for normal intervention group) and tissues were prepared as
previously described. Proteins (50 ug) were boiled in reducing
buffer (final concentrations:16.7 mmol/L Tris-HCl, pH 6.8, 2%
SDS, 0.83% b-mercaptoethanol,3.3% glycerol, and 0.016%
bromophenol blue), electrophoresed in(8% for ATP7A, 10% for
CTR1)SDS-PAGE gel (120 V) and transferred to Polyvinylidene
fluoride membrane (Roch) using 100v for 90 min. Membranes
were blocked with 5% skim milk for 1 h at room temperature, and
incubated with the chicken anti-ATP7A antibody (1:1000, Abcam,
USA) and the goat anti-CTR1 (1:1000, Novus biologicals, USA),
respectively, in Tris-buffered saline containing 0.1% Tween-20
(TBST) at 4uC for 2 h. Membranes were then washed with TBST
and incubated for 1 h at room temperature with peroxidase-
conjugated anti-goat IgG or anti-chicken IgG (1:3000, Protein-
tech, USA) in TBST. Proteins were detected by chemilumines-
cence (Super ECL Plus Detection Reagent, Applygen, China).
Densitometry was used to evaluate immunolabeled protein
intensity. Pixel intensities were quantified using Multi Gauge
software V2.2 (Fujifilm) and their levels were normalized against
b-actin controls.
Oxidative-stress-related biomarkers assay
Sub-brain homogenate preparation. Animals were treated
with PA or deionized water as described above (n=5 for model
intervention group and normal intervention group, n=3 for both
blank control groups, in each time point). The cortex and basal
ganglia of the mice were homogenized in 0.1 mol/L PBS(PH7.3)
at 4uC. The homogenate was centrifuged with 100006g for
10 min at 4uC and the supernatant was collected for oxidative
stress biochemical assay. The supernatant was subjected to the
measurement of the protein contents. We used the BCA protein
assay kit (Thermo Scientific) to quantify protein concentrations.
Oxidative-stress-related biomarker levels were then normalized to
milligram protein.
Assessment of SOD levels. The activity of superoxide
dismutase (SOD) was measured by a modified nitrite method
with a commercial-available kit (Nanjing Jiancheng Bioengineer-
ing Insititute, Jiangsu, China). Superoxide generated by hypoxan-
thine and xanthine oxidase was transformed to nitrite ion by
hydroxylamine. Nitrite ion was measured by color densitometry at
550 nm using a coloring reagent. The least necessary amount of
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defined as 1 U of SOD.
Assessment of MDA levels. For lipid peroxidation assay, we
used a colorimetric microplate assay kit (Beyotime Institute of
biotechnology, Zhejiang, China) to quantify the generation of
malondialdehyde (MDA) according to the protocol. MDA was
determined by measuring the red product, thiobarbituric acid(-
TBA)-MDA, generated by TBA and MDA at 100uC for 15 min at
532 nm absorbance.
Assessment of GSH/GSSG ratio. The concentrations of
total glutathione (T-GSH),reduced glutathione(GSH) and oxidized
disulfide(GSSG) were measured by colorimetric microplate assay
from the kits(Beyotime Institute of biotechnology, Zhejiang,
China).The T-GSH level was determined by the method of 5,5-
Dithio-bis(2-nitrobenzoic acid)(DNTB)-GSSG recycling assay.
GSSG level was measured by measuring the 5-thio-2-nitrobenzoic
acid (TNB) which was measured at 412 nm absorbance. The
amount of reduced GSH was determined by subtracting the
amount of GSSG from the total GSH. Then the GSH/GSSG
ratios were calculated.
Statistics
Data presented in this work corresponded to the arithmetical
mean6SEM. Statistical significance (one-way ANOVA, followed
by post hoc Bonferroni) was performed using SPSS 13.0. Values
were considered to differ significantly at the level of p,0.05.
Acknowledgments
The authors thank Ms Miao-Ying He (Laboratory Animal Center, Sun
Yat-sen University, Guangzhou, China) for breeding the mice.
Author Contributions
Conceived and designed the experiments: XHL DBC. Performed the
experiments: DBC LF XPL. Analyzed the data: DBC. Contributed
reagents/materials/analysis tools: WZ FRL XLL. Wrote the paper: DBC
LF XHL.
References
1. Roberts EA, Schilsky ML (2008) Diagnosis and treatment of Wilson disease: an
update. Hepatology 47: 2089–2111.
2. Brewer GJ, Terry CA, Aisen AM, Hill GM (1987) Worsening of neurologic
syndrome in patients with Wilson’s disease with initial penicillamine therapy.
Arch Neurol 44: 490–493.
3. Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, et al. (2006)
Treatment of Wilson disease with ammonium tetrathiomolybdate: IV.
Comparison of tetrathiomolybdate and trientine in a double-blind study of
treatment of the neurologic presentation of Wilson disease. Arch Neurol 63:
521–527.
4. Stuerenburg HJ (2000) CSF copper concentrations, blood-brain barrier
function, and coeruloplasmin synthesis during the treatment of Wilson’s disease.
J Neural Transm 107: 321–329.
5. Reddy PV, Rao KV, Norenberg MD (2008) The mitochondrial permeability
transition, and oxidative and nitrosative stress in the mechanism of copper
toxicity in cultured neurons and astrocytes. Lab Invest 88: 816–830.
6. Britton RS (1996) Metal-induced hepatotoxicity. Semin Liver Dis 16: 3–12.
7. Porzio S, Iorio R, Vajro P, Pensati P, Vegnente A (1997) Penicillamine-related
neurologic syndrome in a child affected by Wilson disease with hepatic
presentation. Arch Neurol 54: 1166–1168.
8. Petris MJ, Smith K, Lee J, Thiele DJ (2003) Copper-stimulated endocytosis and
degradation of the human copper transporter, hCtr1. J Biol Chem 278:
9639–9646.
9. Lutsenko S, Bhattacharjee A, Hubbard AL (2010) Copper handling machinery
of the brain. Metallomics 2: 596–608.
10. Pase L, Voskoboinik I, Greenough M, Camakaris J (2004) Copper stimulates
trafficking of a distinct pool of the Menkes copper ATPase (ATP7A) to the
plasma membrane and diverts it into a rapid recycling pool. Biochem J 378:
1031–1037.
11. Choi BS, Zheng W (2009) Copper transport to the brain by the blood-brain
barrier and blood-CSF barrier. Brain Res 1248: 14–21.
12. Monnot AD, Behl M, Ho S, Zheng W (2011) Regulation of brain copper
homeostasis by the brain barrier systems: Effects of Fe-overload and Fe-
deficiency. Toxicol Appl Pharmacol.
13. Brewer GJ (2010) Risks of copper and iron toxicity during aging in humans.
Chem Res Toxicol 23: 319–326.
14. Rauch H (1983) Toxic milk, a new mutation affecting cooper metabolism in the
mouse. J Hered 74: 141–144.
15. Allen KJ, Buck NE, Cheah DM, Gazeas S, Bhathal P, et al. (2006)
Chronological changes in tissue copper, zinc and iron in the toxic milk mouse
and effects of copper loading. Biometals 19: 555–564.
16. Bohrer D, Do Nascimento PC, Ramirez AG, Mendonca JK, De Carvalho LM,
et al. (2004) Comparison of ultrafiltration and solid phase extraction for the
separation of free and protein-bound serum copper for the Wilson’s disease
diagnosis. Clin Chim Acta 345: 113–121.
17. Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, et al. (2009) Treatment of
Wilson’s disease with tetrathiomolybdate: V. Control of free copper by
tetrathiomolybdate and a comparison with trientine. Transl Res 154: 70–77.
18. Tapiero H, Townsend DM, Tew KD (2003) Trace elements in human
physiology and pathology. Copper. Biomed Pharmacother 57: 386–398.
19. Niciu MJ, Ma XM, El Meskini R, Ronnett GV, Mains RE, et al. (2006)
Developmental changes in the expression of ATP7A during a critical period in
postnatal neurodevelopment. Neuroscience 139: 947–964.
20. Minghetti M, Leaver MJ, Taggart JB, Casadei E, Auslander M, et al. (2011)
Copper induces Cu-ATPase ATP7A mRNA in a fish cell line, SAF1. Comp
Biochem Physiol C Toxicol Pharmacol 154: 93–99.
21. Lee J, Prohaska JR, Dagenais SL, Glover TW, Thiele DJ (2000) Isolation of a
murine copper transporter gene, tissue specific expression and functional
complementation of a yeast copper transport mutant. Gene 254: 87–96.
22. Tennant J, Stansfield M, Yamaji S, Srai SK, Sharp P (2002) Effects of copper on
the expression of metal transporters in human intestinal Caco-2 cells. FEBS Lett
527: 239–244.
23. Halliwell B, Gutteridge JM (1984) Oxygen toxicity, oxygen radicals, transition
metals and disease. Biochem J 219: 1–14.
24. Gaetke LM, Chow CK (2003) Copper toxicity, oxidative stress, and antioxidant
nutrients. Toxicology 189: 147–163.
25. Jomova K, Vondrakova D, Lawson M, Valko M (2010) Metals, oxidative stress
and neurodegenerative disorders. Mol Cell Biochem 345: 91–104.
26. Gaetke LM, Chow CK (2003) Copper toxicity, oxidative stress, and antioxidant
nutrients. Toxicology 189: 147–163.
27. Sansinanea AS, Cerone SI, Streitenberger SA, Garcia C, Auza N (1998)
[Oxidative effect of hepatic copper overload]. Acta Physiol Pharmacol Ther
Latinoam 48: 25–31.
28. Ozcelik D, Uzun H (2009) Copper intoxication; antioxidant defenses and
oxidative damage in rat brain. Biol Trace Elem Res 127: 45–52.
29. Zhang SS, Noordin MM, Rahman SO, Haron J (2000) Effects of copper
overload on hepatic lipid peroxidation and antioxidant defense in rats. Vet Hum
Toxicol 42: 261–264.
30. Ozcelik D, Ozaras R, Gurel Z, Uzun H, Aydin S (2003) Copper-mediated
oxidative stress in rat liver. Biol Trace Elem Res 96: 209–215.
31. Cheng J, Ma H, Fan C, Zhang Z, Jia Z, et al. (2011) Effects of Different Copper
Sources and Levels on Plasma Superoxide Dismutase, Lipid Peroxidation, and
Copper Status of Lambs. Biol Trace Elem Res.
32. Sakurai H, Kamada H, Fukudome A, Kito M, Takeshima S, et al. (1992)
Copper-metallothionein induction in the liver of LEC rats. Biochem Biophys
Res Commun 185: 548–552.
Impact of Penicillamine on the Brain of Tx Mice
PLoS ONE | www.plosone.org 14 May 2012 | Volume 7 | Issue 5 | e37709